Provider: Wright Reports
Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG Reaffirms FY 2012 Operating Loss Guidance-Conference Call
Basilea Pharmaceutica AG announced that it has not changed guidance and expects operating loss, which is similar to the cash burn, is around CHF6 million or CHF7 million per month for fiscal 2012.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation For Treatment Of zygomycosis By U.S.
- Basilea Pharmaceutica AG And Astellas Pharma Inc Reports Positive Topline Phase 3 Results For Antifungal Isavuconazole
- Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation By U.S. FDA
- Basilea Pharmaceutica AG's Board Proposes Martin Nicklasson To Succeed Chairman Werner Henrich
Latest Key Developments in Pharmaceuticals
- FDA approves Gilead Sciences Inc's Sovaldi the treatment of Chronic Hepatitis C
- Auxilium Pharmaceuticals Inc's drug to treat bent penis condition gets U.S. approval - Reuters
- Innovus Pharmaceuticals Inc receives product license approval of EjectDelay for premature ejaculation from Health Canada
- GSK and Theravance announce positive results from pivotal phase iii study for fluticasone furoate/vilanterol in asthma
- Share this
- Digg this